Pharma News
This Week
Sep 28, 2025
Why Pfizer's Prospects After COVID Appear More Promising Than Ever - The Globe and Mail
Pfizer's COVID-19 product sales have plummeted, with Comirnaty and Paxlovid generating only $945 million and $918 million, respectively, in the first half of 2025. However, the company is optimistic about its future, driven by cancer treatments acquired from Seagen, particularly Padcev, which saw a 38% sales increase. Elrexfio also shows promise in treating multiple myeloma.
